Effectiveness and safety of atorvastatin/ ezetimibe fixed-dose combination in hypercholesterolemia: a systematic review and network meta-analysis
PeerJ · 2026
DOI: 10.7717/peerj.21784 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PeerJ, 2026. Verfasst von Juying Qian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Atorvastatin, Ezetimibe, Hypercholesterolemia, Anticholesteremic Agents. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Organon (Shanghai) Pharmaceutical Technology Co., Ltd.
Abstract (Originalsprache)
Background
Many patients fail to achieve low-density lipoprotein cholesterol (LDL-C) targets with statin monotherapy, calling for a combination of statins and ezetimibe. This systematic review and network meta-analysis evaluated the comparative effectiveness and safety of atorvastatin monotherapy, atorvastatin/ezetimibe free-equivalent combination (AS/EZ FEC), and fixed-dose combination (AS/EZ FDC) in patients with hypercholesterolemia.
Methods
Randomized controlled trials were retrieved from electronic databases. Primary outcomes were the percentage change in LDL-C from baseline and LDL-C goal attainment, analyzed using mean difference (MD) and risk ratio (RR) with 95% confidence intervals (CI). Treatments were ranked via surface under the cumulative ranking curve (SUCRA). The two combination therapies were compared to AS alone for their safety profiles and tolerability. Forty-six trials ( n = 10,567) were included.
Results
AS/EZ FDC reduced LDL-C more than AS alone (MD −13.94%, 95% CI [−18.90% to −9.10%]), with similar results for AS/EZ FEC (MD −12.41%, 95% CI [−14.61% to −10.22%]). SUCRA rankings for LDL-C reduction were FDC (86.2%), FEC (63.8%), and AS (0.0%). For LDL-C goal attainment, the RR was 1.87 (95% CI [1.47–2.39]) for FEC vs. monotherapy, 1.80 (95% CI [0.85–3.81]) for FDC vs. monotherapy. No significant differences in safety profiles were observed between treatments.
Conclusion
AS/EZ combination therapies provide greater improvements in LDL-C reduction and goal attainment compared with AS monotherapy, with FDC ranking highest in LDL-C reduction. Treatment with AS/EZ FEC or FDC did not increase the risk of adverse events compared to AS monotherapy and was well tolerated. These findings support FDC use when intensive LDL-C lowering is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Medical Affairs and Outcomes Research, Organon China, Shanghai, China.
Förderung
- Organon (Shanghai) Pharmaceutical Technology Co., Ltd
Zitieren
APA
Qian, J., Zhang, X., Li, Q., & Chen, S. (2026). Effectiveness and safety of atorvastatin/ ezetimibe fixed-dose combination in hypercholesterolemia: a systematic review and network meta-analysis. PeerJ. https://doi.org/10.7717/peerj.21784
Vancouver
Qian J, Zhang X, Li Q, Chen S. Effectiveness and safety of atorvastatin/ ezetimibe fixed-dose combination in hypercholesterolemia: a systematic review and network meta-analysis. PeerJ. 2026. doi:10.7717/peerj.21784
BibTeX
@article{Qian2026,
author = {Qian, Juying and Zhang, Xingxin and Li, Qing and Chen, Sisi},
title = {Effectiveness and safety of atorvastatin/ ezetimibe fixed-dose combination in hypercholesterolemia: a systematic review and network meta-analysis},
journal = {PeerJ},
year = {2026},
doi = {10.7717/peerj.21784}
}
EUVIMED